Latest:
Dr. Facciabene on Radiation Bridging Therapy Prior to CAR T-Cell Therapy in Mice Models
Andrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.
Authors
Alexis LeVee, MD
Alexis LeVee, MD, is chief Hematology & Medical Oncology fellow at City of Hope
Latest:
Dr LeVee on ADC Trials That May Inform the Evolution of Breast Cancer Management
Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.
Costanza Lo Cascio, PhD
Latest:
A New Take on Preclinical Drug Trials for GBM Treatment
The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to subvert this pattern of clinical failure for promising therapeutics by changing the way preclinical studies are developed and conducted to assess the efficacy of drugs for GBM.
Efstathios Kastritis, MD
Latest:
Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.
Aimaz Afrough, MD
Latest:
Discussing the Treatment Options for RRMM Following Progression After BCMA CAR T Therapy
Panelists discuss how various treatment options, including selinexor-based regimens, B-cell maturation antigen (BCMA)–targeted therapies, bispecific antibodies, and CELMoDs, can be used to manage relapsed/refractory multiple myeloma following progression on BCMA-directed chimeric antigen receptor T-cell therapy (CAR T).
Timothy I Shaw, PhD
Latest:
Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors
Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.
Nicholas J. Short, MD
Latest:
Understanding How to Best Measure MRD Negativity in Ph+ ALL
The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.
Catherine Lee, MD
Latest:
The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of Agave-201
Dr. Catherine Lee presents a post-hoc analysis of the AGAVE-201 trial, demonstrating that axatilimab achieves consistent overall response rates in patients with chronic graft-versus-host disease regardless of prior lines of therapy, with rapid and durable responses, particularly following ruxolitinib, and a favorable safety profile.
Timothy Cloughesy, MD
Latest:
INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation
Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.
Christian Grohe, MD, Evangelical Lung Cancer Hospital
Latest:
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.